Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 13/20 | 0.48 |
| ▸ | GUCY1A2 | P33402 | 13/20 | 0.48 |
| ▸ | GUCY1A1 | Q02108 | 13/20 | 0.48 |
| ▸ | GUCY1B1 | Q02153 | 13/20 | 0.48 |
| ▸ | BUB1 | O43683 | 3/20 | 0.40 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23787988 | 0.91 | GUCY1B2 (0.48) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1BUB1 | |
| SCHEMBL17621215 | 0.88 | GUCY1B2 (0.51) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL16081768 | 0.87 | GUCY1B2 (0.50) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL16906879 | 0.86 | GUCY1B2 (0.47) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL19456637 | 0.86 | GUCY1B2 (0.47) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL16906967 | 0.86 | GUCY1B2 (0.51) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL16806614 | 0.85 | GUCY1B2 (0.49) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1BUB1 | |
| SCHEMBL23787907 | 0.85 | GUCY1B2 (0.46) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL17621213 | 0.85 | GUCY1B2 (0.52) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL23666457 | 0.85 | GUCY1B2 (0.47) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11357777-B2 | Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH) | CYCLERION THERAPEUTICS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3411026-B1 | USE OF STIMULATORS OF SOLUBLE GUANYLATE CYCLASE FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) | CYCLERION THERAPEUTICS INC (US) | 2022-03-09 | — | — | EP | disclosed |
| EP-3194382-B1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2021-09-08 | — | — | EP | disclosed |
| US-20210221793-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2021-07-22 | — | — | US | disclosed |
| US-20210161893-A1 | USE OF sGC STIMULATORS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) | CYCLERION THERAPEUTICS, INC. | 2021-06-03 | — | — | US | disclosed |
| US-20190284168-A1 | PYRAZOLE DERIVATIES AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC | 2019-09-19 | — | — | US | disclosed |
| US-20190031641-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2019-01-31 | — | — | US | disclosed |
| WO-2018111795-A2 | USE OF SGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20170291889-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-10-12 | — | — | US | disclosed |
| US-20170291889-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-10-12 | — | — | US | disclosed |
| WO-2017136309-A1 | USE OF sGC STIMULATORS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| WO-2016044447-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221793-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | PTGIS, GMPS, NOS3 | GUCY1B2 22/4885GUCY1A2 15/4885GUCY1A1 19/4885 |
| US-20170291889-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | PTGIS, GMPS, NOS3 | GUCY1B2 22/4885GUCY1A2 15/4885GUCY1A1 19/4885 |
| US-20190284168-A1 | PYRAZOLE DERIVATIES AS SGC STIMULATORS | PTGIS, GMPS, NOS3 | GUCY1B2 23/4885GUCY1A2 15/4885GUCY1A1 16/4885 |
| US-11357777-B2 | Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH) | GLS2, GPR119, PRKG1 | GUCY1B2 16/4885GUCY1A2 9/4885GUCY1A1 8/4885 |
| US-20190031641-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | PTGIS, GMPS, NOS3 | GUCY1B2 22/4885GUCY1A2 15/4885GUCY1A1 19/4885 |
| US-20210161893-A1 | USE OF sGC STIMULATORS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) | GLS2, GPR119, PRKG1 | GUCY1B2 16/4885GUCY1A2 9/4885GUCY1A1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.